May 4, 2026
32‑patient UCL trial: preoperative pembrolizumab linked to no recurrences at 33‑month follow‑up in MMR‑deficient / MSI‑high bowel cancer
A small clinical trial led by University College London and UCL Hospitals enrolled 32 patients with stage 2 or 3 bowel (colorectal) cancer whose tumors were MMR‑defi...